Andrea Lobo,  —

Soliris (eculizumab) was used to effectively treat atypical hemolytic uremic syndrome (aHUS) in a young woman with systemic lupus erythematosus (SLE), another autoimmune condition, a case report shows. The therapy was safely discontinued without causing an aHUS relapse, while immunosuppressant treatments for SLE were maintained. This “case highlights…

A woman in her early 30s who developed pregnancy-associated atypical hemolytic-uremic syndrome (aHUS) after the birth of her baby saw her kidney function recover after being treated with Ultomiris (ravulizumab-cwvz), according to a case report. Clinicians diagnosed the rare condition a week after her first symptoms — which…

Colombian children seen for the first time for atypical hemolytic uremic syndrome (aHUS) had a high frequency of disease manifestations involving organs other than the kidneys, with two-thirds showing signs of lung involvement, a study reports. Their prognosis was worse than reported in previous studies, with more than half…

An 8-year-old girl was diagnosed with a rare case of atypical hemolytic uremic syndrome (aHUS) and cardiac arrhythmias, or abnormal heartbeats, according to a recent report from Turkey. While known for its damage to the kidneys, aHUS can affect the heart, with cases of heart muscle disease and heart failure…

A mutation in the complement factor I (CFI) gene can lead in rare cases to both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy, two complement-mediated kidney diseases, a case study in Japan shows. “Overlapping [aHUS] and C3 glomerulopathy with complement factor I mutation is very rare, especially in…

Both Soliris (eculizumab) and Ultomiris (ravulizumab) are safe, and have similar effectiveness in improving kidney function and blood parameters in people with atypical hemolytic syndrome (aHUS), according to a new systematic review study. However, Ultomoris “was preferred by a majority of the patients as it only has…

A group of blood disorders called hypereosinophilia syndrome, known as HES, was suspected to be the trigger event that led to atypical hemolytic uremic syndrome (aHUS) in a woman in her late 30s, according to a new case study. HES is caused by an overload of eosinophils, a type…

Short-term use of Soliris (eculizumab) successfully treated atypical hemolytic uremic syndrome (aHUS) that had no genetic link in two young adults, one with a rare infection and the other with a rare autoimmune condition, according to a case report. Both men lacked variants in complement genes that can…

Reduced capillary density and capillary abnormalities were identified in people with atypical hemolytic uremic syndrome (aHUS) using a nailfold dermoscopy, a study in Turkey reports. Nailfold dermoscopy is a noninvasive technique that lets doctors evaluate the small blood vessels (capillaries) in the nail fold. These observations suggest the technique…

A synthetic psychoactive drug was identified as the trigger that led to the onset of atypical hemolytic uremic syndrome (aHUS) in a 37-year-old man who was genetically prone to develop the condition, a case study in Croatia reported. “Our case is the first report of aHUS with proven ……